ArticleInfection and drug resistance2020
Molecular Investigations of Linezolid Resistance in Enterococci
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Molecular Detection of Linezolid Resistance Determinants and Identification of a Novel C2626T Mutation in Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2026Article
- Epidemiological and Genomic Insights into Linezolid-Non-Susceptible Enterococci in Pediatric Patients.Current microbiology · 2026Article
- Article
- Bacterial contamination level and characterization of antimicrobial-resistant bacteria in commercial pet foods in Japan.One health (Amsterdam, Netherlands) · 2025Article
- Molecular Characteristics and Antimicrobial Resistance of Linezolid-ResistantInfection and drug resistance · 2025Article
- Molecular Characterization of Linezolid-Non-SusceptibleInfection and drug resistance · 2025Article
- Genomic Characterization and Phylogenetic Analysis of Linezolid-Resistant Enterococcus from the Nostrils of Healthy Hosts Identifies Zoonotic Transmission.Current microbiology · 2024Article
- Genomic epidemiology reveals multiple mechanisms of linezolid resistance in clinical enterococci in China.Annals of clinical microbiology and antimicrobials · 2024Article
- Linezolid Resistance Genes and Mutations among Linezolid-SusceptibleAntibiotics (Basel, Switzerland) · 2024Article
- Prevalence and genetic diversity ofFrontiers in microbiology · 2024Article
- A Genomic Snapshot of Antibiotic-ResistantGlobal health, epidemiology and genomics · 2023Article
- Review
- Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2022Article
- Emergence ofInfection and drug resistance · 2022Article
- Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.Clinical microbiology reviews · 2021Article
- Comparison of Anti-Microbic and Anti-Biofilm Activity Among Tedizolid and Radezolid Against Linezolid-ResistantInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe OptrA protein is a member of ATP-binding cassette (ABC) transporters, a transporter family which can confer resistance to oxazolidinone antibiotics by transferring plasmid. We aim to describe the distribution of
methodsLinezolid-resistance-related genes were tested for
resultsAmong 20
conclusionOptrA exists in linezolid non-resistant enterococci with diverse amino acid substitutions. The variants play different roles in changing the MIC of linezolid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.